Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
58,361.12 +800.58 (+1.39%) CMC Crypto 200
1,260.28 -10.46 (-0.82%)
BIO Sep 2024 430.000 call
| Previous close | 13.00 |
| Open | 13.00 |
| Bid | 2.45 |
| Ask | 11.90 |
| Strike | 430.00 |
| Expiry date | 2024-09-20 |
| Day's range | 13.00 - 13.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
ZacksEarnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif., May 01, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).
ZacksAnalysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
